» Articles » PMID: 16804414

Association of SH-2 Containing Inositol 5'-phosphatase 2 Gene Polymorphisms and Hyperglycemia

Overview
Journal Pancreas
Specialty Gastroenterology
Date 2006 Jun 29
PMID 16804414
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: SH-2 containing inositol 5'-phosphatase 2 (SHIP2) is a family of inositol 5'-phosphatases, which possess the 5'-phosphatase activity that hydrolyzes phosphatidylinositol-3, 4, 5-trisphosphate to phosphatidylinositol-3, 4-bisphosphate and is suspected to negatively regulates the metabolic signaling of insulin. To clarify the possible involvement of SHIP2 in physiological abnormalities, we examined the human SHIP2 gene polymorphism in a Japanese cohort.

Methods: We searched single-nucleotide polymorphisms (SNPs) on the human SHIP2 gene promoter and 5'-untranslated region (5'-UTR) and investigated their relationship with impaired fasting glycemia (IFG) in a Japanese cohort. Next, the effect of the SNPs on promoter activity was examined in HeLa and HL60 cells.

Results: Among the several SNPs detected on the human SHIP2 gene promoter and 5'-UTR, 3 SNPs (-405 C/A, +57 G/A, and +334 C/T) formed the haplotypes CGC and AAT and were found at a relatively high frequency in the Japanese population. The frequency of genotypes (+334 CT and TT) was significantly higher in the group with IFG than in the normal group (P < 0.0001, odds ratio = 2.23, 95% confidence interval = 1.50-3.32). This association was not affected by age and gender. Furthermore, one haplotype (+57 A, +334 T) which was inserted into a luciferase reporter plasmid and existed more frequently in the IFG group than in the normal group exhibited increased promoter activity in the culture cells compared with the other haplotype (+57 G, +334 C).

Conclusions: The SNPs in the SHIP2 gene promoter and the 5'-UTR may account partly for the IFG and may be a marker for the risk of diabetes.

Citing Articles

Novel Sulfonanilide Inhibitors of SHIP2 Enhance Glucose Uptake into Cultured Myotubes.

Berg M, Naams J, Hautala L, Tolvanen T, Ahonen J, Lehtonen S ACS Omega. 2020; 5(3):1430-1438.

PMID: 32010815 PMC: 6990439. DOI: 10.1021/acsomega.9b02944.


SHIPping out diabetes-Metformin, an old friend among new SHIP2 inhibitors.

Lehtonen S Acta Physiol (Oxf). 2019; 228(1):e13349.

PMID: 31342643 PMC: 6916339. DOI: 10.1111/apha.13349.


INPPL1 gene mutations in opsismodysplasia.

Fradet A, Fitzgerald J J Hum Genet. 2016; 62(2):135-140.

PMID: 27708270 PMC: 5268411. DOI: 10.1038/jhg.2016.119.


Evidence for SH2 domain-containing 5'-inositol phosphatase-2 (SHIP2) contributing to a lymphatic dysfunction.

Agollah G, Gonzalez-Garay M, Rasmussen J, Tan I, Aldrich M, Darne C PLoS One. 2014; 9(11):e112548.

PMID: 25383712 PMC: 4226566. DOI: 10.1371/journal.pone.0112548.


Discovery and development of small molecule SHIP phosphatase modulators.

Viernes D, Choi L, Kerr W, Chisholm J Med Res Rev. 2013; 34(4):795-824.

PMID: 24302498 PMC: 4991215. DOI: 10.1002/med.21305.